Clinical Trials Sponsored by Intarcia Therapeutics

Total 6333 results

Acorda Therapeutics

Completed

Single Ascending Doses of GGF2 in Patients With Left Ventricular Dysfunction and Symptomatic Heart Failure (GGF2-1101-1)

Heart Failure

United States
Corcept Therapeutics

Terminated

A Study to Confirm Recurrent or Persistent Cushing's Syndrome in Patients With Signs or Symptoms of Hypercortisolemia

Cushing's Syndrome

United States
Ocera Therapeutics

Terminated

Safety and Efficacy of AST-120 in Patients With GERD Who Continue to be Symptomatic on a Standard Dose of PPI

Gastroesophageal Reflux Disease (GERD)

United States
Ocera Therapeutics

Terminated

Safety and Efficacy of AST-120 in the Treatment of Antibiotic-Refractory Pouchitis

Pouchitis

United States
Corcept Therapeutics

Completed

An Extension Study of CORLUX in the Treatment of Endogenous Cushing's Syndrome

Cushing's Syndrome

United States
United Therapeutics

Terminated

Open-Label Study of Oral Treprostinil in Digital Ulcers (DISTOL-EXT)

Systemic Sclerosis

United States, Canada, United Kingdom
Aeris Therapeutics

Terminated

A Continuation Study of the AeriSeal® System Administered at 3 to 4 Sites During a Single Treatment Session for Lung Volume Reduction in Patients With Advanced Emphysema

Lung Diseases | Pulmonary Emphysema | Chronic Obstructive Pulmonary Disease(COPD)

Israel
Aeris Therapeutics

Terminated

Post Market Registry Study of the AeriSeal System

Pulmonary Emphysema

Germany, Israel
Aeris Therapeutics

Terminated

A Registry Study of the AeriSeal® System or Lung Volume Reduction in Patients With Advanced Emphysema

Emphysema | Chronic Pulmonary Obstructive Disease

Germany, Israel, Austria, France
vTv Therapeutics

Completed

A 6 Week Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of GK1-399 in Type 2 Diabetes

Type 2 Diabetes Mellitus

United States
Acorda Therapeutics

Completed

Study of Fampridine-ER Tablets in Patients With Multiple Sclerosis

Multiple Sclerosis

United States
Corcept Therapeutics

Completed

A Study of the Efficacy and Safety of CORLUX in the Treatment of Endogenous Cushing's Syndrome (SEISMIC)

Cushing's Syndrome

United States
Alaunos Therapeutics

Unknown

Effect on QTc, Pharmacokinetics, Safety, and Preliminary Efficacy of Single-agent Palifosfamide-tris in Subjects With Advanced Solid Tumors

Advanced Solid Tumors

United States
Egetis Therapeutics

Completed

Mangafodipir as an Adjunct to Percutaneous Coronary Intervention (MANAMI)

Myocardial Infarction

Sweden
Aeris Therapeutics

Completed

AeriSeal System for Lung Volume Reduction

Lung Diseases | Emphysema | Pulmonary Emphysema | Chronic Obstructive Pulmonary Disease (COPD)

Israel, Austria, France, Germany
Chelsea Therapeutics

Completed

Study of the Fed-Fast Pharmocokinetics and Bioequivalance of 300mg Capsules of Droxidopa

Symptomatic Neurogenic Orthostatic Hypotension

United States
Argos Therapeutics

Completed

Study Testing the Biologic Activity and Safety of an Immunotherapeutic in Patients With Newly Diagnosed Stage IV Kidney Cancer

Renal Cell Carcinoma

Canada, United States
United Therapeutics

Terminated

A Study of MAb-3F8 Plus Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus 13-cis-Retinoic Acid (RA) Plus GM-CSF in Primary Refractory Neuroblastoma Patients

Primary Refractory Neuroblastoma

United States
United Therapeutics

Completed

Safety Evaluation of Inhaled Treprostinil Administration Following Transition From Inhaled Ventavis in Pulmonary Arterial Hypertension (PAH) Subjects

Pulmonary Arterial Hypertension

United States
Cardium Therapeutics

Unknown

Angiogenesis in Women With Angina Pectoris Who Are Not Candidates for Revascularization (AWARE)

Angina Pectoris

United States
Vicus Therapeutics

Completed

Regimen for the Treatment of Cachexia in Subjects With NSCLC (VT-122)

Cachexia

India, United States
Argos Therapeutics

Completed

A Single-Patient Study Using AGS 006

Pancreatic Cancer

United States
Argos Therapeutics

Completed

Phase II Study of AGS-004 as an Immunotherapeutic in Antiretroviral Therapy (ART)-Treated Subjects Infected With HIV

HIV Infections

Canada, United States
Ascenta Therapeutics

Terminated

An Open-label, Single-center, Phase 1/ 2 Study of Chemoradiotherapy and AT-101 in Patients With Locally Advanced Esophageal or Gastroesophageal Junction Cancer

Locally Advanced Esophageal or GE Junction Cancer

United States
Acorda Therapeutics

Completed

Pharmacokinetics (PK) of Dalfampridine-ER 7.5 mg BID in Healthy Volunteers and Subjects With Mild or Moderate Renal Impairment

Renal Insufficiency

United States
Sangamo Therapeutics

Completed

Clinical Trial of SB-509 in Subjects With Amyotrophic Lateral Sclerosis (ALS) (ALS)

Amyotrophic Lateral Sclerosis

United States
Allon Therapeutics

Completed

Study to Evaluate Safety, Tolerability, and Effect of AL208 on Mild Cognitive Impairment Following Coronary Artery Bypass Graft Surgery

Mild Cognitive Impairment

United States, Canada
Capstone Therapeutics

Completed

A Phase 2a Study to Evaluate the Safety and Efficacy of AZX100 in Trocar Sites of Arthroscopic Shoulder Surgery Patients

Scar Prevention | Scar Reduction

United States
Precision Therapeutics

Terminated

Correlation of the Chemoresponse Assay With PFS in Patients With Recurrent Epithelial Ovarian, Peritoneal, or Fallopian Tube Cancer

Peritoneal Neoplasms | Ovarian Cancer | Fallopian Tube Cancer

United States
Alaunos Therapeutics

Completed

Phase II Study of ZIO-101 in Advanced Blood and Bone Marrow Cancers

Hematologic Neoplasms | Non-Hodgkin's Lymphoma | Bone Marrow Neoplasms

United States
Alaunos Therapeutics

Completed

Phase I Study of Indibulin in Patients With Solid Tumors

Solid Tumors

Netherlands
Alaunos Therapeutics

Unknown

Phase I Study in Advanced Solid Tumors

Solid Tumors

United States
Alaunos Therapeutics

Completed

A Phase I Trial of ZIO-101 in Solid Tumors

Solid Tumors

United States
Alaunos Therapeutics

Completed

Phase IB Study of Indibulin Using Positron-Emission Tomography (PET) Scans

Advanced Cancer

United States
United Therapeutics

Withdrawn

Safety and Efficacy of Inhaled Treprostinil in Patients With PAH (INTREPID)

Pulmonary Arterial Hypertension
United Therapeutics

Withdrawn

Inhaled Treprostinil for PAH: Open-label Extension (INTREPID - OL)

Pulmonary Arterial Hypertension
Pathfinder Therapeutics

Completed

Evaluation of a Minimally Invasive Image-Guided Surgery System for Hepatic Ablation Procedures

Liver Cancer

United States
Acorda Therapeutics

Completed

Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients With Multiple Sclerosis

Multiple Sclerosis

United States, Canada
Acorda Therapeutics

Completed

Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients With Multiple Sclerosis Who Participated in the MS-F204 Trial

Multiple Sclerosis

United States, Canada
Corcept Therapeutics

Completed

An International Extension Study of Corlux for Recurrent Psychotic Symptoms in Psychotic Major Depression

Psychotic Disorders | Major Depressive Disorder

Bulgaria, Croatia, Romania, Serbia
Chroma Therapeutics

Completed

A Study of the Safety and Tolerability of the Addition of CHR-2797 to Paclitaxel in Patients With Advanced or Refractory Tumours

Solid Tumor

Netherlands
Corcept Therapeutics

Completed

A United States Study of Corlux for Psychotic Symptoms in Psychotic Major Depression

Psychotic Disorders | Major Depressive Disorder

United States
Corcept Therapeutics

Completed

An International Study of the Safety and Tolerability of Corlux for Psychotic Symptoms in Psychotic Major Depression

Major Depressive Disorder

Bulgaria, Croatia, Romania, Former Serbia and Montenegro
Argos Therapeutics

Completed

An Investigation of AGS-009 in Patients With Systemic Lupus Erythematosus (SLE)

Inflammation | Systemic Lupus Erythematosus (SLE)

United States
Chroma Therapeutics

Completed

Safety and Tolerability of CHR-2845 to Treat Haematological Diseases or Lymphoid Malignancies (CHR-2845-001)

Lymphoid Malignancies | Hematological Disease

France, Belgium, Netherlands
Mateon Therapeutics

Completed

Study Evaluating the Safety and Response of Fosbretabulin in Asian Patients With Polypoidal Choroidal Vasculopathy (PCV)

Polypoidal Choroidal Vasculopathy

United States, Hong Kong, Korea, Republic of, Singapore, Taiwan
Aeris Therapeutics

Completed

US 10 mL Biologic Lung Volume Reduction (BLVR) Phase 2 Emphysema Study

Pulmonary Emphysema

United States
Aeris Therapeutics

Completed

A Dose Ranging Study of the Aeris Polymeric Lung Volume Reduction (PLVR) System in Patients With Advanced Upper Lobe Predominant Emphysema

Advanced Emphysema

Germany
Mateon Therapeutics

Completed

Safety Study of Increasing Doses of Combretasatin A1 Diphosphate (OXi4503) as Monotherapy in Subjects With Hepatic Tumor Burden (OXi4503)

Neoplasm Metastasis

Australia
Ascenta Therapeutics

Completed

Safety and Efficacy Study of AT-101 in Combination With Docetaxel and Prednisone in Men With HRPC

Prostate Cancer

United States

3

Subscribe